Proteostasis, mitochondrial quality control and neural stem-cell niches form the nervous system's repair capacity. This deep dive maps each system and the failure points our preclinical work targets.
Neurons are among the longest-lived cells in the body, and they carry the maintenance burden that longevity implies. Repair in neural tissue is not a single pathway but a layered system: misfolded protein clearance, mitochondrial turnover, membrane and axonal remodelling, and — in restricted niches — the generation of new cells. Neurodegenerative disease is best understood as the progressive exhaustion of those layers rather than a single catastrophic event.
Proteostasis: the first line of maintenance
The proteostasis network couples chaperone-assisted folding, ubiquitin-proteasome degradation and autophagy. In healthy neurons these three arms compensate for each other. Under chronic misfolding load, compensation narrows: chaperone capacity saturates, proteasome throughput falls, and autophagic flux becomes the rate-limiting step. Aggregate species that were previously transient begin to persist.
- Chaperone saturation is measurable before visible aggregate burden appears.
- Proteasome and autophagy readouts must be interpreted together; either alone is misleading.
- Flux assays, not steady-state levels, distinguish an active pathway from a blocked one.
Mitochondrial quality control
Neurons depend on tightly localised ATP supply, so mitochondrial defects appear first as functional deficits at the synapse rather than as global bioenergetic collapse. Fission, fusion and mitophagy determine whether damaged organelles are repaired, isolated or removed. Where mitophagy is impaired, damaged mitochondria persist in distal compartments and raise local oxidative load.
Regenerative niches and their limits
Adult neurogenesis is restricted, but supporting populations — oligodendrocyte precursors, astrocytes, microglia — retain substantial regenerative capacity. Chronic inflammatory signalling pushes these populations toward reactive states that trade repair for containment. Restoring a permissive niche is therefore as much an immunological problem as a stem-cell problem.
What this means for preclinical design
- Measure repair capacity under load, not at baseline.
- Pair every molecular readout with a functional assay.
- Treat glial state as an independent variable, not background noise.
This article describes preclinical research. Cytosomatic Labs does not treat patients, sell products or provide medical advice.